Skip to main content
. Author manuscript; available in PMC: 2023 Jan 3.
Published in final edited form as: Biol Blood Marrow Transplant. 2017 Mar 15;23(7):1064–1071. doi: 10.1016/j.bbmt.2017.03.017

Figure 2:

Figure 2:

Transplant outcome stratified by residual disease status.

(A) Cumulative incidence of relapse and (B) overall survival by MFC MRD, (C) Cumulative incidence of relapse and (D) overall survival by NGS, (E) Cumulative incidence of relapse and (F) overall survival by tandem assessment using MFC and NGS. In (E) and (F), patients with discordant assessment are grouped together as their outcome tracked with patients in the F−/M− group.

F denotes MFC, M denotes mutation analysis by NGS and status is categorized as +/−